anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ORTHO EVRA (norelgestromin and ethinyl estradiol) is a once-a-week transdermal contraceptive (birth control) system where a small square-shaped patch is worn on the body and hormones from the patch are absorbed transdermally (through the skin) to help prevent pregnancy. This is an observational case-control study that will use data provided by a United States health care claims database and the National Death Index (NDI) to assess the risk of venous thromboembolism abbreviated as VTE (includes deep vein thrombosis abbreviated as DVT \[a blood clot that forms in one or more of the deep veins of the body, usually the legs\] and pulmonary embolism abbreviated as PE \[a blood clot in the lungs\]), acute myocardial infarction abbreviated as AMI (heart attack), and ischemic stroke (blockage of an artery that supplies blood to the brain) among women using the transdermal contraceptive system, ORTHO EVRA compared with women using norgestimate-containing oral contraceptives (NGM-OCs) with 35 mcg ethinyl estradiol (EE), during the period 01 April 2002 to 31 December 2004 and during an extension period from 01 January 2005 to 31 December 2006. In the extension period of the study (01 January 2005 to 31 December 2006), mortality was added as an endpoint in the study. After obtaining Institutional Review Board (IRB) approval and a waiver of authorization, requests will be made for medical records for all women who have been dispensed at least once with ORTHO EVRA or a NGM-OC and whose health insurance claims are consistent with the occurrence of VTE, AMI, or stroke. The primary outcome measure in the study is AMI and ischemic stroke combined in current and recent users or ORTHO EVRA compared to current and recent users of NGM-OCs with 34 mcg of EE. Observational study - No investigational drug administered. NOTE: The study was conducted in two parts. Study CR014383, NCT00511784, represents the first portion of the study. This study, CR012022, represents the second portion of the extended study.
Antibodies and uses targeting SARS-CoV-2 receptor binding regions are disclosed. The antibody comprises a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises a CDR1 shown as SEQ ID NO.7, a CDR2 shown as SEQ ID NO.8 and a CDR3 shown as SEQ ID NO.9, and the light chain variable region comprises a CDR1 shown as SEQ ID NO.10, a CDR2 shown as SEQ ID NO.11 and a CDR3 shown as SEQ ID NO. 12. The monoclonal antibody provided by the invention has remarkable neutralizing and inhibiting capacity on novel coronaviruses and various mutant strains thereof. In addition, the fusion inhibition model shows that the monoclonal antibody of the invention can effectively prevent the fusion of target cells with SARS-CoV-2 effector cells. The invention solves the technical problem that the treatment method aiming at RBD fails in the prior art.
This is an open-label, single center, sequentially study in subjects with chronic stroke. Considering 20% dropout rate (based on evaluable versus treated patients), approximately 15 subjects will be enrolled, and at least 12 subjects will be evaluable. Cohort 1 will recruit the first 3 evaluable subjects assigned to receive low dose of GXNPC-1. The following 3 evaluable subjects will be enrolled sequentially and treated with high dose of GXNPC-1 in cohort 2. In cohort 3, another 6 evaluable subjects will be enrolled to take high dose of GXNPC-1. There will be 2 parts of this study including GXNPC-1 preparation and GXNPC-1 treatment in chronic stroke subjects, respectively.
Continuous flow left ventricular assist devices (CF-LVADs) have been shown to reduce mortality and morbidity in patients with advanced heart failure with reduced ejection fraction. However, ventricular arrhythmias (VA) are common, are mostly secondary to underlying myocardial scar, and have a higher incidence in patients with pre-LVAD VA. Sustained VA is well tolerated in the LVAD patient but can result in implantable defibrillator (ICD) shocks, right ventricular failure, hospitalizations, and reduced quality of life. There is limited data regarding best practices for the medical management of VA as well as the role for procedural interventions in patients with uncontrolled VA and/or ICD shocks. Vast majority of CF-LVAD patients have a preexisting cardiovascular implantable electronic device (CIED) and ICD and/or cardiac resynchronization therapies are continued in many. Several questions, however, remain regarding the efficacy of ICD and CRT following CF-LVAD. Moreover, optimal CIED programming after CF-LVAD implantation. Therefore, the primary objective of this review article is to provide the most up-to-date evidence and to provide guidance on the clinical significance, pathogenesis, predictors, and management strategies for VA and ICD therapies in the CF-LVAD population. We also discuss knowledge gaps as well as areas for future research.
The sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions.
The experimental product is 100% L-citrulline. Each pod will contain 10 grams of L-citrulline. Ten grams of L-citrulline provide 2.4 g of nitrogen.
PROBLEM TO BE SOLVED: To obtain a water-soluble or water-dispersible polymer salt by blending a polymer having a free acid group (PA) and a neutralizer containing a compound having a free amino group (VA) or a polymer having a free amino group (PB) and a compound having a free acid group (VB) where each of these compounds has a hydrophilic group. SOLUTION: The acid groups for the components PA and VB are preferably each carboxylic acid or sulfonic acid group. The amino groups for the components PB and VA are preferably each a tertiary amino group. The components PA and PB are each selected from a polyurethane, a poly(meth) acrylate, a poly(meth)acrylamide, a polymer containing pyrrolidone and their mixture. For the component VA, N-methyldipropylene triamine, α,ω- diaminopolyether or the like is used. The component VB is a linear or branched 6-40C dicarboxylic acid or a 6-40C polycarboxylic acid.
The invention comprises a method of screening cecal microflora for in vitro competition against select enteric pathogens, as well as the characterization of specific cecal microflora. The invention also comprises using the characterized competitive exclusion culture against select enteric pathogens in poultry, porcine, and ruminant, and humans. Selection of competitive isolates was achieved by combining  Salmonella enteritidis  (SE), adult broiler cecal microflora, and an indicator broth, which was then placed in a microtiter plate. Potential isolates were then challenged individually against  Salmonella enteritidis.  The ability of the selective isolates was determined by qualitative evaluation of  Salmonella  growth on brilliant green agar after the challenge. Isolates analyzed included but are not limited to;  Bacillus  species,  Staphylococcus  species,  Escherichia  species,  Citrobacter  species,  Enterococcus  species,  Proteus  species,  Enterobacter  species,  Salmonella  species, and  Klebsiella  species. Each isolate from genera with potential pathogens was further safety-tested by intraperitoneal injection or airsac injection and evaluated for morbidity, mortality, and lesions. We demonstrate that the incidence of SE recovery was markedly reduced by treatment with nine selected isolates which were individually amplified, under aerobic conditions, and then re-combined prior to administration.
FIELD: medicine, oncology, phytotherapy. SUBSTANCE: method involves selective removal of cicutotoxin from water-hemlock tincture. Tincture is prepared by infusion of 10 g of dried or 5 g of crude water-hemlock roots or rhizomes with 100 g of 70% ethyl alcohol for 10 days. After filtration activated carbon is added to tincture at ratio 1 part of activated carbon per 10 parts of tincture followed by shaking every 2 h for 2 days. Then the end product is filtered off through paper filter. Invention provides the possibility of oral use of tincture. EFFECT: improved method of preparing. 2 cl, 4 ex
Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The vegetarian patty (Impossible Burger) will be 18% fat.
PURPOSE: Provided are a composition, pharmaceutical or agricultural composition and a seed using bioabsorbable, biocompatible polymeric synthetic wax which has a low melting point and a low viscosity to permit solvent free processing technology in production of a medical device and a composition. CONSTITUTION: The medical device includes a synthetic, bioabsorbable, biocompatible polymeric wax comprising the reaction product of a polybasic acid or derivative thereof, a fatty acid; and a polyol. The polymeric wax having a melting point less than about 70 deg. C, as determined by differential scanning calorimetry. The composition comprises an effective amount of a bioactive agent, and a wax comprising the reaction product of a polybasic acid or derivative thereof, a fatty acid and a polyol, the wax having a melting point less than about 70 deg. C, as determined by differential scanning calorimetry. The seed comprises a coating of a synthetic, bioabsorbable, biocompatible polymeric wax comprising the reaction product of a polybasic acid or derivative thereof, a fatty acid, and a polyol, the polymeric wax having a melting point less than about 70 deg. C, as determined by differential scanning calorimetry.
The execution of a clinical trial is supported in the following manner. Patient model data is provided for modeling a patient-level workflow in the clinical trial in accordance with a trial protocol. Clinical data of patients participating in the clinical trial is accessed. Using a workflow engine, an instance of the patient-level workflow is instantiated for each of the patients to obtain a plurality of patient-level workflow instantiations. Each of the patient-level workflow instantiations is executed independently based on the clinical data of each respective one of the patients. The patient model data may include or be linked to a rule associated with a step of the patient-level workflow. The rule may be executed when the workflow engine reaches the step in one of the patient-level workflow instantiations. Accordingly, a virtual representation of the clinical trial on a patient-level is obtained which represents the actual state of the clinical trial yet which is computer-accessible. Having such a virtual representation of the clinical trial allows the clinical trial to be easily monitored, actively managed, etc., thereby facilitating its execution.
The pharmacokinetics, efficacy and safety of glimepiride have been evaluated in pediatric patients with type 2 diabetes as described below. Glimepiride is not recommended in pediatric patients because of its adverse effects on body weight and hypoglycemia. 

The pharmacokinetics of a 1 mg single dose of glimepiride was evaluated in 30 patients with type 2 diabetes (male = 7; female = 23) between ages 10 and 17 years. The mean (± SD) AUC (0-last) (339±203 ng•hr/mL), C max (102±48 ng/mL) and t 1/2 (3.1±1.7 hours) for glimepiride were comparable to historical data from adults (AUC (0-last) 315±96 ng•hr/mL, C max 103±34 ng/mL and t 1/2 5.3±4.1 hours). 

The safety and efficacy of glimepiride in pediatric patients was evaluated in a single-blind, 24-week trial that randomized 272 patients (8 to 17 years of age) with type 2 diabetes to glimepiride (n=135) or metformin (n=137). Both treatment-naïve patients (those treated with only diet and exercise for at least 2 weeks prior to randomization) and previously treated patients (those previously treated or currently treated with other oral antidiabetic medications for at least 3 months) were eligible to participate. Patients who were receiving oral antidiabetic agents at the time of study entry discontinued these medications before randomization without a washout period. Glimepiride was initiated at 1 mg, and then titrated up to 2, 4, or 8 mg (mean last dose 4 mg) through Week 12, targeting a self- monitored fasting fingerstick blood glucose < 126 mg/dL. Metformin was initiated at 500 mg twice daily and titrated at Week 12 up to 1000 mg twice daily (mean last dose 1365 mg). 

After 24 weeks, the overall mean treatment difference in HbA1c between glimepiride and metformin was 0.2%, favoring metformin (95% confidence interval -0.3% to +0.6%).

Based on these results, the trial did not meet its primary objective of showing a similar reduction in HbA1c with glimepiride compared to metformin.

The profile of adverse reactions in pediatric patients treated with glimepiride was similar to that observed in adults [see Adverse Reactions ( 6)]. 

Hypoglycemic events documented by blood glucose values <36 mg/dL were observed in 4% of pediatric patients treated with glimepiride and in 1% of pediatric patients treated with metformin. One patient in each treatment group experienced a severe hypoglycemic episode (severity was determined by the investigator based on observed signs and symptoms).
Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by certain criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy (Depression- Mania Rating Scale, Clinical Global Assessment Scale,Quality of life, adherence to treatment.
We report the case of a laryngectomized patient with an enlarged tracheoesophageal puncture (TEP) that is refractory to standard treatments and culminating in life-threatening recurrent dislodgement and aspiration of custom fabricated dual extra-large flange voice prostheses (VP). The fabrication and use of a novel intraluminal prosthetic device to prevent dislodgement, lessen aspiration, and preserve TE voice is described. A custom device insetting a commercial VP into the posterior wall of a LaryTube (coined "inset-VP") was devised with the primary goal of eliminating chronic VP dislodgement and lessening aspiration while maintaining TE voice. Tools required to fabricate the device included a commercial laryngectomy tube, standard-flanged commercial indwelling voice prosthesis, felt-tip marker, 6 mm biopsy punch, and silk suture. After 7 months of using an inset-VP LaryTube device, the patient has experienced zero episodes of VP aspiration. Thin liquid aspiration control is equivalent or better than prior management with custom 24-30 mm dual collar prostheses. TEP voice is fluent and functional with device in place. Novel strategies are needed to manage the rare but devastating effects of a severely enlarged TEP. Solutions to manage symptoms need to be patient-specific, aligning with their anatomy, physiology, psychosocial needs, and goals. The inset-VP device described in this report may offer improved prosthetic retention in select patients with enlarged TE puncture and frequent VP dislodgements.
The prevalence of obesity is increasingly widespread, resembling a global epidemic. Lifestyle changes, such as consumption of high-energy-dense diets and physical inactivity, are major contributors to obesity. Common features of this metabolic pathology involve an imbalance in lipid and glucose homeostasis including dyslipidemia, insulin resistance and adipose tissue dysfunction. Moreover, the importance of the gut microbiota in the development and susceptibility to obesity has recently been highlighted. In recent years, new strategies based on the use of functional foods, in particular bioactive peptides, have been proposed to counteract obesity outcomes. In this context, the present study examines the effects of a lupin protein hydrolysate (LPH) on obesity, dyslipidemia and gut dysbiosis in mice fed a high-fat diet (HFD). After 12 weeks of LPH treatment, mice gained less weight and showed decreased adipose dysfunction compared to the HFD-fed group. HFD-induced dyslipidemia (increased triglycerides, cholesterol and LDL concentration) and insulin resistance were both counteracted by LPH consumption. Discriminant analysis differentially distributed LPH-treated mice compared to non-treated mice. HFD reduced gut ecological parameters, promoted the blooming of deleterious taxa and reduced the abundance of commensal members. Some of these changes were corrected in the LPH group. Finally, correlation analysis suggested that changes in this microbial population could be responsible for the improvement in obesity outcomes. In conclusion, this is the first study to show the effect of LPH on improving weight gain, adiposopathy and gut dysbiosis in the context of diet-induced obesity, pointing to the therapeutic potential of bioactive peptides in metabolic diseases.
Six hour smoking cessation online training addressed to health professionals from hospitals in 3 Latin American Countries. Participants are monitored by local coordinators that act as champions. They offer their assistance to log into the online platform, fill out the questionnaires, complete the evaluation, including other technical support. Participants' progress is monitored in real time onto the web platform. The project coordinator at ICO sends a report of the participants progress every other week to coordinators, and if necessary personal emails to motivate students to finish the course and complete the evaluations.
PURPOSE:To obtain the titled cosmetic by providing a receiving mold having a concave upper surface corresponding to the swollen form and a cosmetic pan furnished with a bottom plate having through-holes, covering the receiving mold with the cosmetic pan turned upside down and filling a molten cosmetic through the through-holes into the concave upper surface of the receiving mold. CONSTITUTION:A cosmetic pan 1 furnished with a bottom plate 2 having through-holes 3 is turned upside down and put on a receiving mold 30 having a concave upper surface 31 of e.g. dome-shape. A molten cosmetic 7 is poured on the reverse face of the bottom plate 2 as shown by the arrows until the concave part is filled with the cosmetic 7 and a small amount of cosmetic is overflowed from the through-holes 3 and left on the reverse face of the bottom plate 2. Spill of the residual cosmetic to the circumference is prevented by a protruded edge 4. After solidifying the cosmetic, the cosmetic is separated from the receiving mold 30 and turned upside down to obtain a cosmetic pan 1 holding a cosmetic 7 fixed to the perforated bottom plate 2 and having convex surface 8. It can be produced without using expensive facilities such as press and is easily handleable in use since it is not tightly pressed with a press.
Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96 week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was \> 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to \< 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.
PURPOSE:To provide the titled compound containing tannins and useful as an additive for medicinal drug, foods, cosmetics, etc. CONSTITUTION:A tannin-cyclodextrin clathrate compound is produced by clathrating one or more kinds of tannins (e.g. extract of Geranium thumbergii, geraniin, gambir extract, etc.) with a cyclodextrin (a cyclic oligosaccharide composed of 6-8 glucose units bonded with each other, and produced mainly from dextrin by using enzymes or microorganisms; e.g. beta-cyclodextrin). The compound has various advantages such as the lowering of rough and astringent taste, the prevention of discoloration, the improvement of the stability of tannins, etc., compared with the simple addition of tannin to a food, etc. The discoloration can be prevented and the stability of the tannin can be improved further by adding a metal chelating agent (e.g. edetate, citric acid, etc.) to the above clathrate compound.
Acid reflux can cause inconvenience in life. When getting serious, doctors description is needed to treat the symptoms. However, the symptoms can be treated and prevented by practicing life skills when the symptoms are still at an early stage. The symptoms, which are caused by the fast pace life or diet without the intake of fiber, can be treated by practicing a method of swallowing saliva by moving a tough in mouth. The symptoms can be treated as a patient practices the method of continuously swallowing his saliva while biting a date seed in the mouth or chewing a small amount of chewing gum. Patients may end up in the hospital when the patients do not receive treatment for the symptoms of mild acid reflux. However, the patients can prevent the symptoms from developing by practicing the method of swallowing the saliva in daily life.
PURPOSE: To reinforce the antifungal characteristics of an antifungal medicine by using the nonsteroidal antifungal medicine of lanosterol synthesis inhibitor together with a specific azasterol compound. CONSTITUTION: A 25-azasterol compound of the formula (R is H, a lower acyl; X is CH, CH2 , O; the dotted line is a single line, a double line, etc.)  e.g. 17β-[[3(dimethylamino)propyl]methylamino] androstoene3β-ol(25-azacholesterol)} is administered together with a nonsteroidal antifungal medicine of lanosterol synthesis inhibitor. The nonsteroidal antifungal medicine is used at a semifungistatic dose. The simultaneous use of a compound of formula I, a compound of formula II, a compound of formula III, etc., is especially useful.
The present invention relates to a method for manufacturing herb decoction including the following steps: selecting a medicinal herb pellet assembly or a medicinal herb tea bag according to prescription; extracting the selected medicinal herb pellet assembly or the medicinal herb tea bag by using a solvent; and filtrating the extracts. According to the present invention, the medicinal herb pellet assembly or the medicinal herb tea bag is manufactured in a form of pellets or a tea bag, and is manufactured to have the weight in a certain unit. Therefore, a needed number of the pellet or the tea bag can be used according to the prescription. Accordingly, medicinal herb in a standard form can be distributed. Therefore, consumers such as common people households can use the herb decoction in an easy manner. The herb decoction can be used to be extracted immediately without an additional processing procedure as the medicinal herb is manufactured after being pre-treated.
Povidion iodine will be used as a skin cleanser. povidion iodine will be heated sterile to 38 degrees with a ben-mari method and its temperature will be controlled by degrees. When it reaches the appropriate degree, the skin cleaning of the baby will be done sterile.